BR112022024751A2 - Uso de um inibidor de fosfodiesterase 10 para o tratamento da síndrome de tourette - Google Patents
Uso de um inibidor de fosfodiesterase 10 para o tratamento da síndrome de touretteInfo
- Publication number
- BR112022024751A2 BR112022024751A2 BR112022024751A BR112022024751A BR112022024751A2 BR 112022024751 A2 BR112022024751 A2 BR 112022024751A2 BR 112022024751 A BR112022024751 A BR 112022024751A BR 112022024751 A BR112022024751 A BR 112022024751A BR 112022024751 A2 BR112022024751 A2 BR 112022024751A2
- Authority
- BR
- Brazil
- Prior art keywords
- syndrome
- tourette
- phosphodiesterase
- treatment
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Abstract
USO DE UM INIBIDOR DE FOSFODIESTERASE 10 PARA O TRATAMENTO DA SÍNDROME DE TOURETTE. A presente invenção refere-se a métodos de tratamento da Síndrome de Tourette em um indivíduo em sua necessidade, pela administração ao indivíduo de composições que compreendem um inibidor de PDE10 de Fórmula (I). Também são descritas formas sólidas cristalinas do composto de Fórmula (I) e usos dos mesmos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063035310P | 2020-06-05 | 2020-06-05 | |
US202163160302P | 2021-03-12 | 2021-03-12 | |
PCT/EP2021/065074 WO2021245280A1 (en) | 2020-06-05 | 2021-06-04 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022024751A2 true BR112022024751A2 (pt) | 2023-03-07 |
Family
ID=76325557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022024751A BR112022024751A2 (pt) | 2020-06-05 | 2021-06-04 | Uso de um inibidor de fosfodiesterase 10 para o tratamento da síndrome de tourette |
Country Status (12)
Country | Link |
---|---|
US (1) | US11883385B2 (pt) |
EP (1) | EP4161526A1 (pt) |
JP (1) | JP2023528896A (pt) |
KR (1) | KR20230040978A (pt) |
CN (1) | CN116137811A (pt) |
AU (1) | AU2021285225A1 (pt) |
BR (1) | BR112022024751A2 (pt) |
CA (1) | CA3180793A1 (pt) |
CL (1) | CL2022003400A1 (pt) |
IL (1) | IL298713A (pt) |
MX (1) | MX2022015400A (pt) |
WO (1) | WO2021245280A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3206573A1 (en) * | 2021-01-28 | 2022-08-04 | George GARIBALDI | Methods for the treatment of childhood-onset fluency disorder |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
US8349824B2 (en) | 2010-12-07 | 2013-01-08 | Hoffmann-La Roche Inc. | Triazolopyridine compounds |
MX2015010971A (es) * | 2013-02-27 | 2015-10-26 | Mochida Pharm Co Ltd | Derivado novedoso de pirazol. |
CN105164126B (zh) * | 2013-04-30 | 2017-05-31 | 豪夫迈·罗氏有限公司 | 吡唑酰胺的Pd‑催化偶联 |
-
2021
- 2021-06-04 BR BR112022024751A patent/BR112022024751A2/pt unknown
- 2021-06-04 JP JP2022574676A patent/JP2023528896A/ja active Pending
- 2021-06-04 IL IL298713A patent/IL298713A/en unknown
- 2021-06-04 CA CA3180793A patent/CA3180793A1/en active Pending
- 2021-06-04 AU AU2021285225A patent/AU2021285225A1/en active Pending
- 2021-06-04 KR KR1020237000369A patent/KR20230040978A/ko unknown
- 2021-06-04 EP EP21730917.8A patent/EP4161526A1/en active Pending
- 2021-06-04 MX MX2022015400A patent/MX2022015400A/es unknown
- 2021-06-04 WO PCT/EP2021/065074 patent/WO2021245280A1/en unknown
- 2021-06-04 CN CN202180057821.7A patent/CN116137811A/zh active Pending
-
2022
- 2022-12-01 CL CL2022003400A patent/CL2022003400A1/es unknown
- 2022-12-02 US US18/061,206 patent/US11883385B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP4161526A1 (en) | 2023-04-12 |
CN116137811A (zh) | 2023-05-19 |
US11883385B2 (en) | 2024-01-30 |
KR20230040978A (ko) | 2023-03-23 |
JP2023528896A (ja) | 2023-07-06 |
MX2022015400A (es) | 2023-03-16 |
AU2021285225A1 (en) | 2023-01-19 |
CL2022003400A1 (es) | 2023-07-28 |
CA3180793A1 (en) | 2021-12-09 |
IL298713A (en) | 2023-02-01 |
WO2021245280A1 (en) | 2021-12-09 |
WO2021245280A9 (en) | 2022-01-27 |
US20230149372A1 (en) | 2023-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
EA202190630A1 (ru) | Способы комбинированной терапии | |
BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
EP4285906A3 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
BR0312957A (pt) | Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento | |
NO20080150L (no) | Inhibitorer av AKT-aktivitet | |
NO20092569L (no) | Inhibitorer av Akt-aktivitet | |
BRPI0617165B1 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
BRPI0411016A (pt) | composições antisépticas, processos e sistemas | |
BRPI0312464B8 (pt) | compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos | |
BRPI0818533B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
NO20060978L (no) | Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering | |
BRPI0607330A2 (pt) | composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto | |
BR0209127A (pt) | compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
WO2019152419A8 (en) | Prc2 inhibitors | |
BRPI0513513A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente | |
BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
BRPI0410669A (pt) | inibidores de caspase e usos dos mesmo | |
MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
BRPI0509653A (pt) | inibidores cinesina mitótica | |
BR112017007239A2 (pt) | inibidor da aurora a cinase, seus usos, e composição farmacêutica". | |
BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами |